TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (age range 3 months to 6 years) undergoing craniosynostosis repair, fronto-orbital advancement surgery and cranial remodeling surgery (i.e. total cavernal remodeling surgery).~Exclusion Criteria:~* Preexisting hematological abnormality (defined as a positive history of bleeding disorder or a known diagnosis of a genetic or acquired bleeding disorder)~* Preexisting coagulation defect (defined as PT, PTT or INR \>1.5 times normal or a n pre-existing genetic or acquired coagulation defect))~* Preexisting hepatic, renal, vascular, ocular and/or metabolic disorder~* History of acetylsalicylate ingestion within the last 14 days.~* History of NSAIDs ingestion with 2 days of the scheduled surgery date

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- high dose TXA (Type: EXPERIMENTAL): High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion
- Low Dose TXA (Type: EXPERIMENTAL): Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of ACH with genetic confirmation~2. Age between 2 to 10 years old (inclusive) at Screening Visit~3. Prepubertal (Stage 1 breasts for girls or testicular volume \< 4ml for boys) at Screening Visit~4. Able to stand without assistance~5. Caregiver willing and able to administer subcutaneous injections of study drug~Exclusion Criteria:~1. Clinically significant findings at Screening that:~   * are expected to require surgical intervention during participation in the trial or~  * are musculoskeletal in nature, such as Salter-Harris fractures and severe hip pain or~  * otherwise are considered by investigator or Medical Monitor/Medical Expert to make a participant unfit to receive study drug or undergo trial related procedures~2. Have received treatment (\>3 months) of human growth hormone (hGH) or other medications known to affect stature or body proportionality at any time~3. Have received any dose of medications intended to affect stature or body proportionality within the previous 6 months of Screening Visit~4. Have received any study drug or device intended to affect stature or body proportionality at any time~5. History or presence of injury or disease of the growth plate(s), other than Achondroplasia, that affects growth potential of long bones

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- TransCon CNP 6 mcg (Type: EXPERIMENTAL): TransCon CNP 6 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 20 mcg (Type: EXPERIMENTAL): TransCon CNP 20 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 50 mcg (Type: EXPERIMENTAL): TransCon CNP 50 mcg CNP/kg delivered once weekly by subcutaneous injection.
- TransCon CNP 100 mcg (Type: EXPERIMENTAL): TransCon CNP 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo mimicking 6, 20, 50, or 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
- Open-Label Extension Period (Type: EXPERIMENTAL): Subjects who complete the 52-week blinded treatment period can continue into the 104-week open-label extension period and will receive treatment with TransCon CNP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valchlor in the Treatment of Lichen Planopilaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 18 years or older.~* Biopsy proven diagnosis of Lichen Planopilaris~* Biopsy proven diagnosis of Fontal Fibrosing Alopecia (a clinical variant of LPP restricted to frontal scalp)~* Good general health as confirmed by medical history~* Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and~* Patients who read and sign an approved informed consent for this study~Exclusion Criteria:~* Vulnerable study population~* Pregnant or nursing women~* Women planning a pregnancy within the study period~* Active smokers~* Known history of adverse reaction to mechlorethamine~* Use of systemic immunosuppressive~* Presence of ulcerated scalp lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valchor treatment of Lichen Planopilaris (Type: EXPERIMENTAL): Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with malignant melanoma~* Measurable unresectable Stage III or IV melanoma~* HLA-A\*0201 positive~* Previous treatment with \& failure/relapse/inability to tolerate IL-2, dacarbazine and/or temozolomide~* At least 4 weeks since prior treatment~* Negative pregnancy~* Life expectancy greater than 4 months~* Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1~* Required lab values~* Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) negative~Exclusion Criteria:~* Prior malignancies which the patient has not been disease free for over 5 years, except treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer~* Ocular melanoma~* Active, untreated central nervous system (CNS) metastasis~* Prior treatment with MDX-010 (anti-CTLA4) antibody~* Prior treatment with any cancer therapeutic vaccine~* Active autoimmune disease or history of autoimmune disease~* Pregnancy or nursing~* Hypersensitivity to Incomplete Freund's Adjuvant (IFA) (Montanide ISA-51)~* Underlying medical conditions deemed hazardous if treated with study drug~* Concomitant therapy with anti-melanoma drugs, chemotherapies, other investigational therapies, chronic use of systemic corticosteroids~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
- 2 (Type: EXPERIMENTAL): MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
- 3 (Type: ACTIVE_COMPARATOR): MDX-010 (ipilimumab) + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who provide signed and dated written informed consent~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects who have no known hypersensitivity to any component of Neulasta or MSB11455, and laboratory test results within predefined ranges~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- First MSB11455 Then Neulasta (Type: EXPERIMENTAL): None
- First Neulasta Then MSB11455 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* American Society of Anesthesiologists (ASA) Class 1-3 participants who are scheduled to undergo an elective surgical procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium.~Exclusion criteria:~* Participants with neuromuscular disorders, significant renal dysfunction, malignant hyperthermia, allergy to medications used in general anesthesia and in whom difficult intubation is expected.~* Participants taking medications known to interfere with neuromuscular blocking agents.~* Participants who are of child-bearing potential, pregnant, and breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent.~* Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:~  * \< 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk equivalent~ * \< 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent~ * OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO QD and ezetimibe 10 mg PO QD~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of L-carnitine on Hypothyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypothyroidism with fatigue symptom~* Currently use of the same amount of levothyroxine over at least six months~* Normal serum free T4 level~Exclusion Criteria:~* Current smoker~* Serum hemoglobin level of under 12mg/dL~* Clinical diagnosis of diabetes mellitus or fasting serum glucose level ≥ 126mg/dL or HbA1c level ≥ 6.5%~* History of significant heart failure~* History of large amount of alcohol consumption~* Uncontrolled hypertension (systolic blood pressure ≥ 160 millimeter of mercury (mmHg) or diastolic blood pressure ≥ 100 mmHg~* pregnant, or planning to be pregnant, or breast feeding women~* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 times of normal limit~* serum Cr level \> 2.0mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- L-carnitine (Type: ACTIVE_COMPARATOR): L-carnitine 330mg, 3 tablet twice daily
- Placebo (Type: PLACEBO_COMPARATOR): placebo drug, 3 tablet twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females \>/= 18 years~* Patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for radical prostatectomy or patients with prostate tumor recurrence (Patients with advanced tumor disease and a high likelihood to display lymph node metastasis are to be preferably included.)~* ECOG (Eastern Cooperative Oncology Group) performance status of 0-2, determined within one week prior to treatment with BAY94-9392~* Patient had an \[18F\]-fluorodeoxyglucose (FDG) PET/CT for detection, or staging, or restaging, or therapy response assessment that still showed tumor mass with high certainty for a cancer such as melanoma, or colorectal cancer, or head \& neck cancer for which FDG-PET/CT is used in clinical routine, and the primary cancer disease is histologically confirmed. In case of recurrent disease confirmation of the primary tumor is sufficient~* No clinically relevant deviations in renal function as determined by Cockcroft and Gault method using serum creatinine at screening.~Exclusion Criteria:~* Concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY94-9392, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study~* Known sensitivity to the study drug or components of the preparation~* Previous treatment with BAY94-9392 in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Problem Adaptation Therapy (PATH) vs. Supportive Therapy in Treating Depressed, Cognitively Impaired Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets Diagnostic and Statistical Manual for Mental Disorders(DSM)IV criteria for unipolar major depression~* Severity of depression greater than or equal to 17 on MADRS~* Disability as determined by at least 1 impairment in instrumental activities of daily living~* Evidence of executive dysfunction or impairment in at least one of the following cognitive domains of Dementia Rating Scale (DRS): attention, construction, conceptualization, and memory (\[scaled score less than 7\] adjusted for age and race based on Mayo's older participants normative data)~* Family member or caregiver able and willing to participate in treatment~* Not currently taking antidepressants, cholinesterase inhibitors, or memantine or on a stable dosage for 8 weeks prior to study entry with no medical recommendation for change of these agents in the near future~Exclusion Criteria:~* High suicide risk~* Axis I psychiatric disorder or substance abuse other than unipolar major depression or nonpsychotic depression~* Axis II diagnosis of antisocial personality~* Moderate to severe dementia: DRS total score corresponding to moderate or more severe impairment (scaled score less than or equal to 5)~* Acute or severe medical illness (e.g., delirium; metastatic cancer; decompensated cardiac; liver or kidney failure; major surgery; stroke; myocardial infarction during the 3 months prior to entry)~* Currently taking drugs known to cause depression (e.g., reserpine, alpha-methyl-dopa, steroids)~* Currently receiving psychotherapy~* Aphasia~* Sensory problems~* Inability to speak English

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PATH (Type: EXPERIMENTAL): Participants will receive PATH for 12 weeks
- ST-CI (Type: ACTIVE_COMPARATOR): Participants will receive ST-CI for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Misoprostol for Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for labour induction~* Term pregnancy with alive fetus~* Bishop score less than six~Exclusion Criteria:~* Previous uterine scar~* Nonvertex presentation~* Non-reassuring fetal status~* Fetal anomalies~* Fetal growth restriction~* Genital bleeding~* Tumors, malformations and/or ulcers of vulva, perineum or vagina

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sublingual Misoprostol 12,5mcg (Type: ACTIVE_COMPARATOR): Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
- Vaginal Misoprostol 25 mcg (Type: ACTIVE_COMPARATOR): Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with gastroparesis;~2. Subjects must agree to the use of contraception~3. Ability and acceptance to provide written informed consent;~4. Willing to participate in the pharmacogenomics sample collection;~5. Willing and able to comply with all study requirements and restrictions~6. Willing to not participate in any other interventional trial for the duration of their participation.~Exclusion Criteria:~1. Another active disorder or treatment which could explain or contribute to symptoms in the opinion of the Investigator (including but not limited to gastric malignancy, neurological disorder, or heavy doses of strong anticholinergics);~2. Pregnancy or nursing;~3. History of intolerance and/or hypersensitivity to medications similar to VLY-686 (Tradipitant) and its accompanying excipients;~4. Use of another NK1 antagonist or palonosetron;~5. Exposure to any investigational medication, including placebo, within 60 days of the Baseline Visit;~6. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance, or may confound study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug (Type: EXPERIMENTAL): VLY-686 (Tradipitant) oral capsule for 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete